top of page

Search Results

Results found for "Jana Selent"

Posts (219)

  • Exploring the Breakthroughs in GPCR Research

    heterotrimeric G protein activity biosensors Marta Lopez-Balastegui, Antonella Di Pizio, Jiafei Mao, Jana Selent, et al. for their research on the Relevance of GPCR dynamics for receptor activation, signalling Principles of Pharmacology in Drug Discovery II - Advanced Methods for the Optimization of Candidate Selection

  • 📰 GPCR Weekly News, May 27 to June 2, 2024

    work on Highly biased agonism for GPCR ligands via nanobody tethering Elk Kossatz, Michel Bouvier, Jana Selent, et al. for their study on G protein-specific mechanisms in the serotonin 5-HT2A receptor regulate pancreatic polypeptide from a structural, functional, and therapeutic perspective Structural basis for selectivity

  • GPCR Selectivity Beyond the Receptor

    Biased signaling frameworks centered on receptor conformations have a structural limitation when selectivity specificity to ligand-stabilized receptor conformations; this framework does not fully account for selectivity SBI-553 at NTSR1 functions as a PAM-agonist for arrestin while modulating G protein selectivity through This session with Kenneth Jacobson and Matteo Pavan examines the structural determinants that make selective the orthosteric pocket, with implications for PAM design across GPCRs How P2Y14 antagonists achieve selectivity

View All

Other Pages (59)

  • Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem

    John Streicher on how HSP90 flips direction between brain and spinal cord, why isoform-selective inhibitors Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid The "brain always wins" problem is solved by isoform selectivity, not by dose. With a non-selective HSP90 inhibitor given systemically, the brain effect dominates and pain relief is The route from "intrathecal only" to "oral pill" runs through isoform selectivity.

  • Dr. Robert F. Bruns | Dr. GPCR Ecosystem

    He taught himself chemoinformatics as a way to optimize compound selection for screening, and in 1997 He supported the D1 PAM project in various roles from its inception in 2002 until selection of a clinical

  • Dr. Anita Nivedha: Computational Dynamics of Ligand Bias in GPCR Signaling | Dr. GPCR Ecosystem

    Her work has also explored receptor subtype selectivity and peptide-binding GPCRs, connecting structural Subtype Selectivity Emerges from Subtle Structural Differences Even closely related receptor subtypes Selected Quotes “Communication pathways connect the ligand-binding site to the intracellular signaling Applications to Receptor Selectivity Dr. Nivedha: After that, I extended this work to study subtype selectivity.

View All
bottom of page